AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Autor:	Tolaney SM; Dana-Farber Cancer Institute, Boston, MA., Chan A; Curtin University, Perth, Australia., Petrakova K; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Delaloge S; Institut Gustave Roussy, Villejuif, France., Campone M; Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France., Iwata H; Aichi Cancer Center Hospital, Nagoya, Japan., Peddi PF; Providence Saint John's Cancer Institute, Santa Monica, CA., Kaufman PA; University of Vermont Larner College of Medicine, Burlington, VT., De Kermadec E; Sanofi, Cambridge, MA., Liu Q; Sanofi, Cambridge, MA.; Moderna, Inc, Cambridge, MA., Cohen P; Sanofi, Vitry-sur-Seine, France., Paux G; Sanofi, Cambridge, MA., Wang L; Sanofi, Cambridge, MA., Ternès N; Sanofi, Chilly-Mazarin, France., Boitier E; Sanofi, Chilly-Mazarin, France., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea.
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 20; Vol. 41 (24), pp. 4014-4024. Date of Electronic Publication: 2023 Jun 22.
DOI:	10.1200/JCO.22.02746
Abstrakt:	Purpose: Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (aBC). Patients and Methods: In AMEERA-3 (ClinicalTrials.gov identifier: NCT04059484), an open-label, worldwide phase II trial, patients with ER+/HER2- aBC who progressed in the (neo)adjuvant or advanced settings after not more than two previous lines of endocrine therapy (ET) were randomly assigned 1:1 to amcenestrant or single-agent endocrine treatment of physician's choice (TPC), stratified by the presence/absence of visceral metastases, previous/no treatment with cyclin-dependent kinase 4/6 inhibitor, and Eastern Cooperative Oncology Group performance status (0/1). The primary end point was progression-free survival (PFS) by independent central review, compared using a stratified log-rank test (one-sided type I error rate of 2.5%). Results: Between October 22, 2019, and February 15, 2021, 290 patients were randomly assigned to amcenestrant (n = 143) or TPC (n = 147). PFS was numerically similar between amcenestrant and TPC (median PFS [mPFS], 3.6 v 3.7 months; stratified hazard ratio [HR], 1.051 [95% CI, 0.789 to 1.4]; one-sided P = .643). Among patients with baseline mutated ESR1 ; (n = 120 of 280), amcenestrant numerically prolonged PFS versus TPC (mPFS, 3.7 v 2.0 months; stratified HR, 0.9 [95% CI, 0.565 to 1.435]). Overall survival data were immature but numerically similar between groups (HR, 0.913; 95% CI, 0.595 to 1.403). In amcenestrant versus TPC groups, treatment-emergent adverse events (any grade) occurred in 82.5% versus 76.2% of patients and grade ≥3 events occurred in 21.7% versus 15.6%. Conclusion: AMEERA-3 did not meet its primary objective of improved PFS with amcenestrant versus TPC although a numerical improvement in PFS was observed in patients with baseline ESR1 mutation. Efficacy and safety with amcenestrant were consistent with the standard of care for second-/third-line ET for ER+/HER2- aBC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu